Key Highlights

  • Third-quarter net product Revenue at Revolution Medicines (NASDAQ:RVMD) came to USD 197.6 million, the company's debut in product sales after RASONQUE won FDA approval in August.
  • Relay Therapeutics (NASDAQ:RLAY) absorbed a USD 81.7 million loss, which is USD 0.37 a share, and sits on USD 848.6 million of cash and investments that management thinks can cover operations through 2029.
  • Vir Biotechnology (NASDAQ:VIR) saw its loss move from USD 163.1 million down to USD 96.3 million, reports about USD 901.3 million with no debt, and awaits ECLIPSE 1 topline data slated for the fourth quarter.
  • Xencor (NASDAQ:XNCR) brought in USD 116.5 million of total revenue and USD 39.4 million of net income, or USD 0.50 a diluted share, with a USD 105.0 million Alexion settlement behind much of that.

Revolution Medicines (NASDAQ:RVMD): First RASONQUE Sales Arrive Beside a Wider Loss

Revolution Medicines (NASDAQ:RVMD) released its quarterly filing on November 4, 2026, which covers the three months to September 30. The FDA approved RASONQUE, known generically as daraxonrasib, in August 2026 for adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy or cannot take multiagent therapy. Sales of the product brought in USD 197.6 million, where the prior year had none, and two buyers supplied 71% and 28% of that total, so 99% traces to two buyers, a figure calculated from those shares. The loss expanded to USD 407.5 million, equal to USD 1.90 a share, up from a USD 305.2 million loss, or USD 1.61 a share, a year earlier, because development spending jumped 59% to USD 417.1 million and selling costs climbed 191% to USD 153.3 million. The company's liquid holdings reached USD 3.7 billion across cash, cash equivalents and marketable securities, which management judges enough for at least 12 months of planned activity. A first USD 250.0 million Tranche of a term Loan was drawn in October. The filing does not separate initial stocking from ongoing demand, so steady purchasing has yet to be shown. Launch pace, pricing, reimbursement and Supply are the named risks.

Relay Therapeutics (NASDAQ:RLAY): Runway Into 2029 Depends on Equity Raises and the Zovegalisib Trial

Relay Therapeutics (NASDAQ:RLAY), a clinical-stage precision medicine developer, filed its Quarterly Report on November 4, 2026. No revenue appeared in the quarter. The per-share loss improved to USD 0.37 from USD 0.43, even though the net loss itself was USD 81.7 million against USD 74.1 million, because weighted shares climbed to 219.2 million from 172.4 million. Spending on research came to USD 77.1 million against USD 68.3 million a year earlier, while general and administrative costs ran USD 13.1 million. The balance of cash, cash equivalents and investments reached USD 848.6 million, built through Capital Markets rather than operations. A May follow-on offering netted USD 296.8 million, while the at-the-market program contributed a net USD 159.2 million, and each raise dilutes existing holders. Management says the cash covers operating needs into 2029, though those assumptions could prove wrong. Nine-month losses reached USD 238.7 million, and dividing by three gives a quarterly burn of about USD 80 million, a derived figure rather than one the company reported. Zovegalisib is the centerpiece, currently in the Phase 3 ReDiscover-2 study for previously treated HR+/HER2- breast cancer, and management signals that additional capital will be required.

Vir Biotechnology (NASDAQ:VIR): A Smaller Loss Ahead of ECLIPSE 1 Topline Data

Vir Biotechnology (NASDAQ:VIR) released its quarterly numbers on November 4, 2026. Its pipeline targets chronic hepatitis Delta and cancer, and the company remains in the clinical stage. Compared with USD 163.1 million (USD 1.17 a share) a year before, the loss contracted to USD 96.3 million, or USD 0.57 a share, partly because the prior-year quarter contained a USD 75.0 million milestone payment. Operating expenses fell to USD 104.5 million from USD 173.7 million, while total revenue registered a negative USD 0.2 million. About USD 901.3 million was held in cash, cash equivalents and investments, with no Debt outstanding. During October the company collected USD 90 million from Gilead Sciences, a total that combined a USD 65 million upfront amount with a USD 25 million stake purchase. Topline results from the pivotal ECLIPSE 1 study are due in the fourth quarter of 2026, and ECLIPSE 2 and 3 data follow in the first quarter of 2027. The expanded Phase 2 SOLSTICE dataset is scheduled for presentation on November 8. Management thinks the current balance is adequate for at least a year of activity, though it acknowledges possible further raises that could dilute holders, and trial outcomes remain the central risk.

Xencor (NASDAQ:XNCR): Alexion Settlement Income Makes the Quarter Profitable

Xencor (NASDAQ:XNCR) filed its quarterly report on November 4, 2026. Revenue for the period totaled USD 116.5 million, up from USD 21.0 million, and was driven by USD 29.0 million in milestones and USD 87.5 million in royalties. A settlement with Alexion dated July 29, 2026, concerning U.S. Ultomiris royalties, gives the company USD 105.0 million in two equal USD 52.5 million installments. Split by period, USD 27.6 million went into the second quarter and USD 77.4 million into the third. Profit attributable to the company stood at USD 39.4 million, which works out to USD 0.50 for each diluted share, after a USD 6.0 million loss a year earlier. Since the settlement is a one-time item, the nine-month loss remained at USD 111.2 million, or USD 1.47 a share. Research and Development outlays grew to USD 84.3 million, compared with USD 54.4 million a year before. Liquid holdings, meaning cash and marketable debt securities, stood at USD 555.7 million, a level management considers enough for at least the next twelve months. The lead program, XmAb819, produced confirmed partial responses in five of 11 evaluable patients, or 45.5%, and an FDA meeting is planned for the first half of 2027. Risks center on small patient cohorts and partner milestones that are hard to predict.

Where Things Stand

Not yet. The USD 197.6 million reflects RASONQUE's August approval, but it is a first partial quarter, so the filing cannot show steady demand. Revolution Medicines (NASDAQ:RVMD) reported it while losses expanded to USD 407.5 million, and two customers accounted for 99% of sales. Relay Therapeutics (NASDAQ:RLAY) holds cash into 2029 but has no revenue. Vir Biotechnology (NASDAQ:VIR) is holding for its ECLIPSE 1 readout in the fourth quarter. Xencor's profit rests on a settlement that will not recur. Next checkpoints: fourth-quarter RASONQUE sales, progress in the ReDiscover-2 study, the ECLIPSE 1 readout and the second Alexion payment.